In 2015 it was announced that Cellular Research had been acquired by a Becton Dickson (BD) Life Sciences for an undisclosed amount. With close ties to Stanford and founded by two persons previously of Affymetrix, Cellular Research, Inc., is a biotechnology R&D company focused to enabling high-resolution investigation of single cells and limited samples thereby creating new benchmarks and delivering new capabilities. Molecular Indexing technology enables direct and digital detection of individual mRNA molecules in single cells or rare samples eliminating sampling error, amplification bias and external controls. The same sample can be repeatedly analyzed and compared across multiple platforms with no sample degradation. The firm's initial products are based on patented Molecular Indexing⢠technology, which provides fast, simple, and absolute quantitation of mRNA targets in single cells and small samples. offer the highest precision and sensitivity possible. Precise⢠assays are for example an enabling technology for gene expression analysis. Precise assays offer qPCR users with a higher throughput, higher content, and more precise quantitative tool for profiling hundreds of genes in hundreds to thousands of samples. The inclusion of Molecular Indexes corrects for PCR bias and allows users to determine the absolute transcript counts for genes of interest. Precise assays also offer improvements and upgrades for gene expression applications via standard RNA-seq. The custom generated assays, streamlined library generation methods and data analysis tools offer a simple, turnkey solution without requiring advanced RNA-seq experience. This targeted approach is ideal for validating panels of genes of interest with the option of increasing sample throughput by an order of magnitude without adding additional costs. The high content of Precise assays and their ability to quantify even lowly expressed genes make it a valuable tool for quantitatively profiling complete pathwa
